Rdfos is a high-potency therapeutic agent belonging to the bisphosphonate class, specifically formulated to treat and prevent osteoporosis. The active ingredient, Risedronate Sodium, works by inhibiting bone resorption and increasing bone mineral density, making it a cornerstone in the management of postmenopausal osteoporosis and corticosteroid-induced bone loss. By strengthening the skeletal architecture, Rdfos significantly reduces the risk of debilitating vertebral and hip fractures. This “once-a-week” formulation offers excellent patient compliance, providing a convenient dosing schedule for long-term bone maintenance. To ensure maximum absorption and efficacy, it is designed for early morning administration on an empty stomach. When combined with adequate Calcium and Vitamin D supplementation, Rdfos helps restore bone health and empowers patients to lead a more active, independent life. It is a vital scientific solution in the Human Orthocare range, dedicated to preserving skeletal integrity and preventing age-related bone fragility.